Rate of Drug Approvals are lower than previously reported.January 15, 2014 -
Nature Biotechnology has published peer-reviewed paper co-authored by BIO Industry Analysis and BioMedTracker, highlighting results of a study showing that overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2011 is near 1 in 10, while reports from earlier years showed rate of drug approvals to be 1 in 5 to 1 in 6. Study also shows that large molecule drugs are twice as successful in gaining approval compared to small molecule drugs.
New Study Shows the Rate of Drug Approvals Lower than Previously Reported
Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
Press release date: January 9, 2014
WASHINGTON--Today, Nature Biotechnology published a peer-reviewed paper co-authored by the Biotechnology Industry Organization (BIO) Industry Analysis and BioMedTracker (BMT) highlighting results of a study showing that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2011 is near one in 10. Previous reports, taken from earlier years, showed the rate of drug approvals is one in five to one in six.
“This groundbreaking study highlights the depth and breadth of risk inherent in the drug development process more comprehensively than any other previous study”
“This groundbreaking study highlights the depth and breadth of risk inherent in the drug development process more comprehensively than any other previous study,” said Dave Thomas, Director of Industry and Research Analysis at BIO and one of the paper’s lead authors. “Knowing more about the magnitude of risk can lead to smarter drug development as well as smarter investing.”
The study builds on the findings from previous studies and uses a broader, deeper, and larger sample than previous reviews of clinical trials and approvals data using the BioMedTracker (BMT) proprietary database of close to 4,500 drugs and over 7,300 unique development paths.
"Having an up-to-date and detailed picture of clinical success rates, and ultimately how likely a drug is to be approved, is vital to our clients when making investment and business decisions. We believe that this study provides the market with an accurate and comprehensive picture of the relative difficulty of achieving product approval in the U.S.," remarked Michael Hay, Executive Vice President at Sagient Research. "Strikingly, oncology drugs have the toughest time making their way through the clinic, despite cancer being the most closely studied area in drug development. We are very pleased to be able to offer this analysis and provide an in-depth look at the issues facing the industry that lead to these lower rates."
Using clinical trial data from the past nine years, the analysis examines the most recent probability of success by treatment type, phase of development and therapeutic area. Before new therapies hit the market, they have to pass a number of hurdles – meeting regulatory thresholds for efficacy and safety as well as maintaining a competitive internal corporate profitability and marketability profile.
Key findings from the study include:
The overall success rate from Phase I to FDA approval is nearly 10%. This number is comprised of lead and secondary indications.
The study also shows that large molecule drugs are twice as successful in gaining approval compared to small molecule drugs.
The BMT/BIO study examines the clinical Phase status of these development paths as of year-end 2003 through year-end 2011, which accounts for more than 5,800 Phase transitions. The study determines the percentage of drugs that advance to the next Phase of development versus those that are suspended and therefore the likelihood of a drug ultimately being approved by the FDA. The data spans all companies (Big Pharma and biotechnology, both public and private) conducting development on therapeutics for approval in the U.S.
The BMT/BIO analysis includes breakdowns by indication, disease group, size of company, molecule type, route of administration, New Molecular Entity (NME) versus Biologic versus non-NME. The data encompasses the most recent data available during a time in which FDA requirements for approval have been in flux. Included in the analysis is an in-depth look at FDA decisions and approval rates by FDA review number.
The paper is available to Nature Biotechnology subscribers.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
BioMedTracker (www.biomedtracker.com) is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive web-based platform. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Upcoming BIO Events
BIO CEO & Investor Conference
February 10-11, 2014
New York, NY
BIO Asia International Conference
April 8-9, 2014
World Congress on Industrial Biotechnology
May 12-15, 2014
BIO International Convention
June 23-26, 2014
San Diego, CA
Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD
Biotechnology Industry Organization (BIO)
Daniel Seaton, 202-470-5207